Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin increases the activation of aryl hydrocarbon receptor and is associated with the aggressiveness of osteosarcoma MG-63 osteoblast-like cells

Shih Chieh Yang, Chin Hsien Wu, Yuan Kun Tu, Shin Yu Huang, Pai Chien Chou

Research output: Contribution to journalArticle

Abstract

The aryl hydrocarbon receptor (AhR) is a liganddependent transcription factor whose activity is modulated by xenobiotics and physiological ligands. Activation of the AhR by environmental xenobiotics may induce a conformational change in AhR and has been implicated in a variety of cellular processes, including inflammation and tumorigenesis. It is unknown whether the activation of AhR serves a role in modulating the progression of osteosarcoma. The osteosarcoma cell line MG-63, was treated with AhR ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). TCDD treatment degrades AhR expression through activation of the AhR signaling pathway, however there were no survival differences observed in MG-63 cells. There were concomitant elevations of cyclooxygenase-2 and receptor activator of nuclear factor-κB ligand secretion from MG-63 cells upon TCDD treatment on a protein and mRNA level at 24 and 72 h. In addition, TCDD treatment also increases the production of prostaglandin E2 on MG-63 cells, and induces the expression of chemokine receptor CXCR4. However, CXCL12 production was not altered in MG-63 cells when stimulated with TCDD. The AhR antagonist CH-223191, blocks the effects on TCDD-induced RANKL, COX-2, PGE2 and CXCR4 changes. In conclusion, these findings suggest that AhR signal therapy should be further explored as a therapeutic option for the treatment of osteosarcoma.

Original languageEnglish
Pages (from-to)3849-3857
Number of pages9
JournalOncology Letters
Volume16
Issue number3
DOIs
Publication statusPublished - Sep 1 2018
Externally publishedYes

Fingerprint

Aryl Hydrocarbon Receptors
Osteosarcoma
Osteoblasts
Xenobiotics
Ligands
Dinoprostone
Polychlorinated Dibenzodioxins
Chemokine Receptors
Cyclooxygenase 2
Cytoplasmic and Nuclear Receptors
Carcinogenesis
Transcription Factors
Inflammation
Cell Line
Messenger RNA

Keywords

  • 2,3,7,8-tetrachlorodibenzo-p-dioxin
  • Aryl hydrocarbon receptor
  • Osteoblast
  • Osteosarcoma
  • Receptor activator of nuclear factor κΒ ligand

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin increases the activation of aryl hydrocarbon receptor and is associated with the aggressiveness of osteosarcoma MG-63 osteoblast-like cells. / Yang, Shih Chieh; Wu, Chin Hsien; Tu, Yuan Kun; Huang, Shin Yu; Chou, Pai Chien.

In: Oncology Letters, Vol. 16, No. 3, 01.09.2018, p. 3849-3857.

Research output: Contribution to journalArticle

@article{4293e2b785d7482088fc45b2d10f4cbb,
title = "Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin increases the activation of aryl hydrocarbon receptor and is associated with the aggressiveness of osteosarcoma MG-63 osteoblast-like cells",
abstract = "The aryl hydrocarbon receptor (AhR) is a liganddependent transcription factor whose activity is modulated by xenobiotics and physiological ligands. Activation of the AhR by environmental xenobiotics may induce a conformational change in AhR and has been implicated in a variety of cellular processes, including inflammation and tumorigenesis. It is unknown whether the activation of AhR serves a role in modulating the progression of osteosarcoma. The osteosarcoma cell line MG-63, was treated with AhR ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). TCDD treatment degrades AhR expression through activation of the AhR signaling pathway, however there were no survival differences observed in MG-63 cells. There were concomitant elevations of cyclooxygenase-2 and receptor activator of nuclear factor-κB ligand secretion from MG-63 cells upon TCDD treatment on a protein and mRNA level at 24 and 72 h. In addition, TCDD treatment also increases the production of prostaglandin E2 on MG-63 cells, and induces the expression of chemokine receptor CXCR4. However, CXCL12 production was not altered in MG-63 cells when stimulated with TCDD. The AhR antagonist CH-223191, blocks the effects on TCDD-induced RANKL, COX-2, PGE2 and CXCR4 changes. In conclusion, these findings suggest that AhR signal therapy should be further explored as a therapeutic option for the treatment of osteosarcoma.",
keywords = "2,3,7,8-tetrachlorodibenzo-p-dioxin, Aryl hydrocarbon receptor, Osteoblast, Osteosarcoma, Receptor activator of nuclear factor κΒ ligand",
author = "Yang, {Shih Chieh} and Wu, {Chin Hsien} and Tu, {Yuan Kun} and Huang, {Shin Yu} and Chou, {Pai Chien}",
year = "2018",
month = "9",
day = "1",
doi = "10.3892/ol.2018.9098",
language = "English",
volume = "16",
pages = "3849--3857",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin increases the activation of aryl hydrocarbon receptor and is associated with the aggressiveness of osteosarcoma MG-63 osteoblast-like cells

AU - Yang, Shih Chieh

AU - Wu, Chin Hsien

AU - Tu, Yuan Kun

AU - Huang, Shin Yu

AU - Chou, Pai Chien

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The aryl hydrocarbon receptor (AhR) is a liganddependent transcription factor whose activity is modulated by xenobiotics and physiological ligands. Activation of the AhR by environmental xenobiotics may induce a conformational change in AhR and has been implicated in a variety of cellular processes, including inflammation and tumorigenesis. It is unknown whether the activation of AhR serves a role in modulating the progression of osteosarcoma. The osteosarcoma cell line MG-63, was treated with AhR ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). TCDD treatment degrades AhR expression through activation of the AhR signaling pathway, however there were no survival differences observed in MG-63 cells. There were concomitant elevations of cyclooxygenase-2 and receptor activator of nuclear factor-κB ligand secretion from MG-63 cells upon TCDD treatment on a protein and mRNA level at 24 and 72 h. In addition, TCDD treatment also increases the production of prostaglandin E2 on MG-63 cells, and induces the expression of chemokine receptor CXCR4. However, CXCL12 production was not altered in MG-63 cells when stimulated with TCDD. The AhR antagonist CH-223191, blocks the effects on TCDD-induced RANKL, COX-2, PGE2 and CXCR4 changes. In conclusion, these findings suggest that AhR signal therapy should be further explored as a therapeutic option for the treatment of osteosarcoma.

AB - The aryl hydrocarbon receptor (AhR) is a liganddependent transcription factor whose activity is modulated by xenobiotics and physiological ligands. Activation of the AhR by environmental xenobiotics may induce a conformational change in AhR and has been implicated in a variety of cellular processes, including inflammation and tumorigenesis. It is unknown whether the activation of AhR serves a role in modulating the progression of osteosarcoma. The osteosarcoma cell line MG-63, was treated with AhR ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). TCDD treatment degrades AhR expression through activation of the AhR signaling pathway, however there were no survival differences observed in MG-63 cells. There were concomitant elevations of cyclooxygenase-2 and receptor activator of nuclear factor-κB ligand secretion from MG-63 cells upon TCDD treatment on a protein and mRNA level at 24 and 72 h. In addition, TCDD treatment also increases the production of prostaglandin E2 on MG-63 cells, and induces the expression of chemokine receptor CXCR4. However, CXCL12 production was not altered in MG-63 cells when stimulated with TCDD. The AhR antagonist CH-223191, blocks the effects on TCDD-induced RANKL, COX-2, PGE2 and CXCR4 changes. In conclusion, these findings suggest that AhR signal therapy should be further explored as a therapeutic option for the treatment of osteosarcoma.

KW - 2,3,7,8-tetrachlorodibenzo-p-dioxin

KW - Aryl hydrocarbon receptor

KW - Osteoblast

KW - Osteosarcoma

KW - Receptor activator of nuclear factor κΒ ligand

UR - http://www.scopus.com/inward/record.url?scp=85050376295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050376295&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.9098

DO - 10.3892/ol.2018.9098

M3 - Article

VL - 16

SP - 3849

EP - 3857

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -